New pill combo targets tough lymphoma

NCT ID NCT06519526

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests two oral drugs, SHR-0302 and SHR-2554, in about 25 people with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The drugs work by blocking specific proteins that help cancer grow. The study aims to see if the combination is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-0302 (a JAK inhibitor) and SHR-2554 (an EZH2 inhibitor), both taken as pills
What this could lead to: If successful, this combination could offer a new treatment option for patients with hard-to-treat peripheral T-cell lymphoma.
What could go wrong: This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The drugs may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.